United States Biotechnology & Medical Research

Sagimet Biosciences Inc. (SGMT)

Track

Track

Sagimet Biosciences experienced significant insider selling over the past quarter, totaling approximately $578,900 in net value. Key executives, including Director George Kemble, executed multiple planned divestments following the company's recent earnings report. These transactions occurred amidst a 19.5% stock price increase over ninety days, reflecting active liquidation by leadership during this period of market performance.
Ticker: SGMT Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Sagimet Biosciences Inc.. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
1.4
Kemble George Non-Executive Director
Transaction date
Planned sale
Price
181.91
Quantity 25,990 +11.8%
Value US$2,620,937
1.4
GEORGE KEMBLE Director Non-Executive Director
Transaction date
Proposed sale
Price
390.70
Quantity 4,480
Value US$955,234
1.4
Kemble George Non-Executive Director
Transaction date
Planned sale
Price
10.42
Quantity 36,788 +43.8%
Value US$3,201,282
1.4
GEORGE KEMBLE Director Non-Executive Director
Transaction date
Proposed sale
Price
9.57
Quantity 20,206
Value US$193,371
2.6
Rozek Elizabeth Chief Legal & Admin. Officer Officer
Transaction date
Sale
Price
7.76
Quantity 10,545 -4.5%
Value US$81,832
1.4
Kemble George Non-Executive Director
Transaction date
Planned sale
Price
7.46
Quantity 18,844 -23.3%
Value US$140,529
3.0
Happel David President & CEO Executive Director
Transaction date
Sale
Price
7.76
Quantity 64,051 -8.0%
Value US$497,068
1.4
GEORGE KEMBLE Director; Officer Executive Director
Transaction date
Proposed sale
Price
7.82
Quantity 18,844
Value US$147,360
1.2
Chauche Thierry Chief Financial Officer Officer
Transaction date
Sale
Price
5.36
Quantity 1,312 -7.7%
Value US$7,033
3.0
Happel David President & CEO Executive Director
Transaction date
Sale
Price
5.36
Quantity 12,101 -1.8%
Value US$64,865
2.6
Rozek Elizabeth Chief Legal & Admin. Officer Officer
Transaction date
Sale
Price
5.36
Quantity 2,622 -1.4%
Value US$14,054
2.9
Martins Eduardo Bruno Chief Medical Officer Officer
Transaction date
Sale
Price
5.36
Quantity 3,640 -3.4%
Value US$19,511
1.4
Kemble George Executive Chairman Executive Director
Transaction date
Planned sale
Price
7.69
Quantity 37,688 -31.8%
Value US$289,979
1.4
GEORGE KEMBLE Director; Officer Executive Director
Transaction date
Proposed sale
Price
7.85
Quantity 37,688
Value US$295,851
2.6
Rozek Elizabeth General Counsel and CCO Officer
Transaction date
Sale
Price
9.13
Quantity 10,780 -5.5%
Value US$98,471
2.9
Martins Eduardo Bruno Chief Medical Officer Officer
Transaction date
Sale
Price
9.13
Quantity 8,277 -7.2%
Value US$75,607
3.0
Happel David President & CEO Executive Director
Transaction date
Sale
Price
9.13
Quantity 65,478 -8.7%
Value US$598,115
1.4
Kemble George Executive Chairman Executive Director
Transaction date
Planned sale
Price
3.17
Quantity 23,625 -16.6%
Value US$74,830
1.4
GEORGE KEMBLE Director; Officer Executive Director
Transaction date
Proposed sale
Price
3.09
Quantity 23,625
Value US$73,001
2.6
Rozek Elizabeth General Counsel and CCO Officer
Transaction date
Sale
Price
3.10
Quantity 10,914 -6.4%
Value US$33,830
2.9
Martins Eduardo Bruno Chief Medical Officer Officer
Transaction date
Sale
Price
3.10
Quantity 8,357 -9.3%
Value US$25,910
1.4
Kemble George Executive Chairman Executive Director
Transaction date
Sale
Price
3.10
Quantity 14,062 -9.0%
Value US$43,605
3.0
Happel David President & CEO Executive Director
Transaction date
Purchase
Price
5.27
Quantity 12,100 +1.9%
Value US$63,731
3.0
Happel David President & CEO Executive Director
Transaction date
Purchase
Price
4.10
Quantity 1,600 +0.3%
Value US$6,560
3.0
Happel David President & CEO Executive Director
Transaction date
Purchase
Price
2.35
Quantity 590 +inf%
Value US$1,386
3.7
SEIDENBERG BETH C Non-Executive Director
Transaction date
Purchase
Price
16.00
Quantity 46,875 +inf%
Value US$750,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-17 2026-08-14 PlS Planned sale
1.4
Kemble George
Non-Executive Director
25,990 +11.8%
181.91
US$2,620,937 		25,990 +11.8% 181.91 US$2,620,937
2026-08-14 2026-08-14 PrS Proposed sale
1.4
GEORGE KEMBLE

Director

Non-Executive Director
4,480
390.70
US$955,234 		4,480 390.70 US$955,234
2026-08-12 2026-08-11 PlS Planned sale
1.4
Kemble George
Non-Executive Director
36,788 +43.8%
10.42
US$3,201,282 		36,788 +43.8% 10.42 US$3,201,282
2026-08-11 2026-08-11 PrS Proposed sale
1.4
GEORGE KEMBLE

Director

Non-Executive Director
20,206
9.57
US$193,371 		20,206 9.57 US$193,371
2026-07-22 2026-07-20 S Sale
2.6
Rozek Elizabeth

Chief Legal & Admin. Officer

Officer
10,545 -4.5%
7.76
US$81,832 		10,545 -4.5% 7.76 US$81,832
2026-07-22 2026-07-20 PlS Planned sale
1.4
Kemble George
Non-Executive Director
18,844 -23.3%
7.46
US$140,529 		18,844 -23.3% 7.46 US$140,529
2026-07-22 2026-07-20 S Sale
3.0
Happel David

President & CEO

Executive Director
64,051 -8.0%
7.76
US$497,068 		64,051 -8.0% 7.76 US$497,068
2026-07-20 2026-07-20 PrS Proposed sale
1.4
GEORGE KEMBLE

Director; Officer

Executive Director
18,844
7.82
US$147,360 		18,844 7.82 US$147,360
2026-02-12 2026-02-10 S Sale
1.2
Chauche Thierry

Chief Financial Officer

Officer
1,312 -7.7%
5.36
US$7,033 		1,312 -7.7% 5.36 US$7,033
2026-02-12 2026-02-10 S Sale
3.0
Happel David

President & CEO

Executive Director
12,101 -1.8%
5.36
US$64,865 		12,101 -1.8% 5.36 US$64,865
2026-02-12 2026-02-10 S Sale
2.6
Rozek Elizabeth

Chief Legal & Admin. Officer

Officer
2,622 -1.4%
5.36
US$14,054 		2,622 -1.4% 5.36 US$14,054
2026-02-12 2026-02-10 S Sale
2.9
Martins Eduardo Bruno

Chief Medical Officer

Officer
3,640 -3.4%
5.36
US$19,511 		3,640 -3.4% 5.36 US$19,511
2025-11-21 2025-11-20 PlS Planned sale
1.4
Kemble George

Executive Chairman

Executive Director
37,688 -31.8%
7.69
US$289,979 		37,688 -31.8% 7.69 US$289,979
2025-11-20 2025-11-20 PrS Proposed sale
1.4
GEORGE KEMBLE

Director; Officer

Executive Director
37,688
7.85
US$295,851 		37,688 7.85 US$295,851
2025-07-23 2025-07-21 S Sale
2.6
Rozek Elizabeth

General Counsel and CCO

Officer
10,780 -5.5%
9.13
US$98,471 		10,780 -5.5% 9.13 US$98,471
2025-07-23 2025-07-21 S Sale
2.9
Martins Eduardo Bruno

Chief Medical Officer

Officer
8,277 -7.2%
9.13
US$75,607 		8,277 -7.2% 9.13 US$75,607
2025-07-23 2025-07-21 S Sale
3.0
Happel David

President & CEO

Executive Director
65,478 -8.7%
9.13
US$598,115 		65,478 -8.7% 9.13 US$598,115
2024-07-25 2024-07-23 PlS Planned sale
1.4
Kemble George

Executive Chairman

Executive Director
23,625 -16.6%
3.17
US$74,830 		23,625 -16.6% 3.17 US$74,830
2024-07-23 2024-07-23 PrS Proposed sale
1.4
GEORGE KEMBLE

Director; Officer

Executive Director
23,625
3.09
US$73,001 		23,625 3.09 US$73,001
2024-07-23 2024-07-19 S Sale
2.6
Rozek Elizabeth

General Counsel and CCO

Officer
10,914 -6.4%
3.10
US$33,830 		10,914 -6.4% 3.10 US$33,830
2024-07-23 2024-07-19 S Sale
2.9
Martins Eduardo Bruno

Chief Medical Officer

Officer
8,357 -9.3%
3.10
US$25,910 		8,357 -9.3% 3.10 US$25,910
2024-07-23 2024-07-19 S Sale
1.4
Kemble George

Executive Chairman

Executive Director
14,062 -9.0%
3.10
US$43,605 		14,062 -9.0% 3.10 US$43,605
2024-03-28 2024-03-26 B Purchase
3.0
Happel David

President & CEO

Executive Director
12,100 +1.9%
5.27
US$63,731 		12,100 +1.9% 5.27 US$63,731
2023-12-08 2023-12-07 B Purchase
3.0
Happel David

President & CEO

Executive Director
1,600 +0.3%
4.10
US$6,560 		1,600 +0.3% 4.10 US$6,560
2023-11-20 2023-11-16 B Purchase
3.0
Happel David

President & CEO

Executive Director
590 +inf%
2.35
US$1,386 		590 +inf% 2.35 US$1,386
2023-07-20 2023-07-18 B Purchase
3.7
SEIDENBERG BETH C
Non-Executive Director
46,875 +inf%
16.00
US$750,000 		46,875 +inf% 16.00 US$750,000
2023-07-20 2023-07-18 B Purchase
2.4
NEW ENTERPRISE ASSOCIATES 13 LP
Large shareholder
30,000 +0.8%
16.00
US$480,000 		30,000 +0.8% 16.00 US$480,000
2023-07-20 2023-07-18 S Sale
2.4
NEW ENTERPRISE ASSOCIATES 13 LP
Large shareholder
662 -0.0%
16.00
US$10,592 		662 -0.0% 16.00 US$10,592
Explore more

More insider trading research around Sagimet Biosciences Inc.

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America